DUBLIN and NEW YORK, May 5, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) and Forest Laboratories, Inc. (NYSE: FRX) today announced that the registration statement on Form S-4 filed with the U.S. Securities and Exchange Commission ("SEC") by Actavis plc on March 25, 2014 and amended on May 2, 2014 (the "Form S-4"), which includes a joint proxy statement of Actavis and Forest, was declared effective on May 2, 2014. The Form S-4 is available on the SEC's EDGAR system, and may be accessed at https://www.sec.gov/Archives/edgar/data/1578845/000119312514178606/d686059ds4a.htm.
The companies also announced that they have each scheduled shareholder meetings for Tuesday, June 17, 2014 in connection with Actavis' pending acquisition of Forest.
Actavis' special meeting of shareholders will be held on June 17, 2014 at 8:30 a.m. local time, at 1 Grand Canal Square, Docklands, Dublin 2, Ireland. Forest's special meeting of shareholders will be held on June 17, 2014 at 8:30 a.m. local time, at J.P. Morgan, 270 Park Avenue, New York, New York. Both meetings are being held to seek shareholders' approval in connection with the merger and related matters. Each company's shareholders of record as of the close of business on May 2, 2014 are entitled to vote at their respective meetings.
Actavis and Forest expect to begin mailing a joint proxy statement/prospectus to their respective shareholders in the coming days. This joint proxy statement/prospectus will provide information for shareholders of both companies, as well as instructions for shareholders on voting.About Actavis Actavis plc (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. Actavis has global headquarters in Dublin, Ireland and U.S. administrative headquarters in Parsippany, New Jersey, USA. Actavis develops and manufactures generic, brand, branded generic, legacy brands and Over-the-Counter (OTC) pharmaceutical products and has commercial operations in approximately 60 countries. The Company's North American branded pharmaceuticals business is focused principally in the Women's Health, Urology, Gastroenterology and Dermatology therapeutic categories with a strong pipeline of products in various stages of development. Actavis also has a portfolio of five biosimilar products in development in Women's Health and Oncology. Actavis Global Operations has more than 30 manufacturing and distribution facilities around the world, and includes Anda, Inc., a U.S. pharmaceutical product distributor.